PRGO

Health Technology
$9.81 +1.34%
Back to Screener
Live Volume
296,224
Market Cap
1.36 B
P/E Ratio
-
52W Peak Proximity
%34

ANALYSIS CENTER

AI Rating & Analysis: PRGO stock analysis with hallucination-free AI screener tools — real-time price, volume, P/E ratio, 52-week proximity and sector performance data for Health Technology. AI-powered stock analysis and research platform.
GOD-TIER PROMPT ACTIVE
Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level
10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.
1Executive Summary
2Fair Value
3Fundamental Analysis
4Technical Analysis
5Scenario Analysis
6Competitor Comparison
7Dividend Return
8Risk Analysis
9Catalyst Calendar
10Action Plan
HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.
İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.
Open Advanced Chart
TradingView Charts
• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — PRGO

Perrigo Company plc — Company Profile & Analysis

Perrigo Company plc, founded in 1887, boasts a rich history spanning over a century in the healthcare industry. Originally established in Allegan, Michigan, as a packager of household goods, the company evolved significantly over decades, eventually focusing on over-the-counter (OTC) pharmaceuticals and self-care products. In December 2013, it changed its name to Perrigo Company plc and relocated its headquarters to Dublin, Ireland, reflecting its increasingly global footprint and strategic repositioning. Perrigo's core mission is to make lives better by providing accessible, affordable, and high-quality self-care solutions that empower consumers to proactively manage their health and wellness. This mission is deeply embedded in its operational philosophy, driving its product development, manufacturing, and distribution strategies across diverse markets. The company has consistently aimed to be a leader in the store brand and generic OTC market, offering consumers trusted alternatives to national brands.

Perrigo operates through two primary segments: Consumer Self-Care Americas and Consumer Self-Care International, offering a vast portfolio of health and wellness solutions. Its product lines are extensive, encompassing upper respiratory products (cough suppressants, expectorants, sinus and allergy relief), nutrition products (infant formulas, oral electrolyte beverages), digestive health products (antacids, anti-diarrheal, anti-heartburn), pain and sleep-aids (pain relievers, fever reducers), and oral care products (toothbrushes, floss, whitening products). The company also provides healthy lifestyle products (smoking cessation, well-being), skin care (dermatological care, scar management, lice treatment), women's health (feminine hygiene, contraceptives like Opill), and vitamins, minerals, and supplements. Perrigo leverages its robust R&D capabilities to innovate, focusing on developing new formulations, delivery systems, and expanding indications for existing products. While not a high-tech innovator in the traditional sense, its innovation lies in optimizing manufacturing processes for efficiency and cost-effectiveness, ensuring broad accessibility, and strategically acquiring and developing brands like Compeed, Mederma, Nasonex, and the recently approved Opill, the first over-the-counter birth control pill in the U.S.

Perrigo holds a significant market position as a leading provider of store brand and generic over-the-counter health and wellness products. Its global reach extends across the United States, Europe, and other international markets, serving millions of consumers daily. The company distributes its products through a diverse network including retail drug, supermarket, and mass merchandise chains, e-commerce platforms, wholesalers, pharmacies, drug and grocery retailers, and para-pharmacies. Perrigo's target demographics are broad, encompassing individuals and families seeking cost-effective, reliable self-care solutions for everyday health concerns, from infants requiring specialized nutrition to adults managing chronic conditions or seeking preventative wellness. Its strategy of offering high-quality alternatives to national brands appeals to budget-conscious consumers without compromising efficacy or safety. The company's extensive brand portfolio, including well-known names like Good Sense, Prevacid24HR, Solpadeine, and Physiomer, solidifies its presence in various consumer segments.

Looking ahead, Perrigo is strategically focused on strengthening its position as a global leader in consumer self-care. The company's future outlook involves continued investment in its core brands, particularly those with strong growth potential and market leadership, such as Opill, which represents a significant expansion into women's health. Strategic acquisitions and divestitures are also key components of its growth strategy, aiming to optimize its portfolio for higher-margin, consumer-preferred products. Perrigo is committed to enhancing its digital presence and e-commerce capabilities to meet evolving consumer purchasing habits. Furthermore, the company emphasizes operational excellence, supply chain resilience, and sustainable practices to ensure long-term profitability and market competitiveness. By focusing on innovation in accessible self-care, expanding its global footprint, and leveraging its strong distribution networks, Perrigo aims to deliver sustained value to shareholders while empowering consumers worldwide to take charge of their health.

Economic Moat Perrigo's sustainable competitive advantage stems from its extensive portfolio of established, trusted over-the-counter brands and its leadership in the store brand and generic OTC market, offering high-quality, affordable alternatives. Its vast global manufacturing and distribution network, coupled with strong relationships with major retailers and pharmacies, creates significant barriers to entry for competitors and ensures broad product accessibility. Furthermore, its expertise in regulatory navigation for OTC products, exemplified by the Opill approval, provides a distinct advantage in bringing new self-care solutions to market.
CEO Mr. Patrick Lockwood-Taylor
Employees 8,100
Headquarters Ireland
Market Competitors
Smart Tags
#ConsumerHealth #SelfCare #OTC #Pharmaceuticals #Generics #Wellness #Healthcare #PRGO

Market Insights & Investor Q&A — PRGO

Frequently Asked Questions

How can I use an AI portfolio balancing template for free with no signup?
DocuRefinery offers ready-made AI templates; simply select an instant balancing prompt and run it without creating an account. The data is verified and hallucination-free, so you get a balanced view of PRGO without any registration.
What steps are needed to get objective results with a backtest AI command prompt?
Open DocuRefinery's backtest prompt, input PRGO ticker data, and choose the no signup option. The system quickly processes historical performance and returns an objective report using a free, ready-made template.
How does an insider activity tracker prompt provide real‑time, hallucination‑free data?
The platform supplies a specialized prompt that pulls verified insider trades for PRGO in real time. It runs instantly, requires no registration, and delivers accurate, no‑signup insights.

Deep Analysis

AI‑Powered Ready Solutions for Analyzing PRGO Stock

Modern AI methods transform the analysis of stocks like PRGO by automating risk assessment, trend detection, and balance‑sheet scanning. Instead of building complex Excel models, investors can rely on DocuRefinery's ready-made prompts that deliver a full analysis in seconds.

Users select an instant, verified‑data template to monitor PRGO price movements and volume trends. This eliminates manual data gathering and speeds up decision‑making, while the hallucination‑free output ensures reliability.

The advantage of AI‑driven ready prompts lies in both speed and accuracy. Investors can also customize prompts to match their strategy—whether it’s a risk‑adjusted portfolio balancing template or an insider activity tracker—making sophisticated analysis accessible without any signup.